Transcept Pharmaceuticals Inc. (TSPT) said that the U.S. FDA has expressed continued concerns about the safety profile of insomnia drug Intermezzo based on information in the company's resubmitted NDA.
In a teleconference with the FDA held earlier today, the company expects to receive a complete response letter from the FDA for Intermezzo on or before July 14, 2011, the PDUFA date assigned by the FDA for completion of the Intermezzo NDA review.
Transcept seeks approval to market Intermezzo for use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.